image
Mobile_image
eyebrow
headline

Reach your new horizon

content
Alone or in combination with chemotherapy, ADCETRIS is backed by over a decade of established clinical data and has been a trusted foundation of care that healthcare providers and patients rely on.
collection-container
card-grid-container
collection-item-type
core-card, core-text
headline

ADCETRIS is FDA approved to treat certain types of lymphoma across 8 different indications

content
To start learning about ADCETRIS, click your lymphoma type from the links below.
heading

Certain T-cell lymphomas

body
T-cell lymphoma is a type of blood cancer that makes up less than 15% of non-Hodgkin lymphomas. Peripheral T-cell lymphoma (PTCL) is one type of T-cell lymphoma that develops from mature forms of T cells.


Previously untreated PTCL

Relapsed primary cutaneous anaplastic large cell lymphoma or CD30‑expressing mycosis fungoides

Relapsed systemic anaplastic large cell lymphoma
heading

Diffuse large B-cell lymphoma

body
Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma, a type of blood cancer. This type of lymphoma starts in early forms of white blood cells called B cells.


Certain relapsed or refractory DLBCL
heading

Classical Hodgkin lymphoma

body
Classical Hodgkin lymphoma (cHL) is a blood cancer that starts when lymphocytes, a type of white blood cell, grow out of control.


Previously untreated Stage 3 or 4 cHL

Relapsed cHL

cHL after stem cell transplant

Pediatric previously untreated high risk cHL
image
Mobile_image
headline

ADCETRIS is a well-established treatment backed by over a decade of clinical data

content
  • Nearly 1700 patients with certain types of lymphoma received treatment with ADCETRIS across 8 clinical trials
  • Over 67,000 patients in the US and over 183,000 patients worldwide have been treated with ADCETRIS since 2011


Healthcare providers have relied on the extensive clinical study data of ADCETRIS when treating their patients. Researchers continue to investigate ADCETRIS in clinical trials today.

collection-container
content-container
collection-container-variant
2-column
collection-item-type
core-content, core-text
headline

Talk to your doctor about ADCETRIS

content
Communicating openly with your doctor is an important part of making sure that your treatment is right for you. Your appointment is an opportunity to share symptoms, ask questions, and discuss your treatment goals. These resources are designed to help you feel confident and prepared to have those conversations with your healthcare provider.
icon
headline

ADCETRIS patient brochure

content

This brochure is intended to help build knowledge and confidence through a detailed overview of ADCETRIS and can help inform treatment discussions with your doctor.

English

Spanish

icon
headline

Doctor Discussion Guide

content
It's important to ask questions and share concerns about ADCETRIS treatment with a doctor. The Doctor Discussion Guide can help you navigate the conversation, so you get the most out of your visit. Take this printable PDF with you to your next appointment.

View the guide
headline

Glossary

content

FDA: The US Food and Drug Administration.

Lymphoma: A type of blood cancer that starts in the cells of the immune system (or lymphatic system).

Mycosis fungoides (MF): Mycosis fungoides mainly affects the skin and is the most common type of cutaneous T-cell lymphoma, occurring in about 50% of cases.

Primary cutaneous anaplastic large cell lymphoma (pcALCL): A type of non-Hodgkin lymphoma that involves the skin.

Refractory: When cancer does not respond or stopped responding to treatment.

Relapse: When cancer has returned after signs and symptoms of cancer had reduced or became undetectable.

Systemic anaplastic large cell lymphoma (sALCL): A fast-growing type of T-cell lymphoma. It may appear in the skin, lymph nodes, bones, soft tissues, lungs, or liver.